LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, cancer, phase, sarcomas, patients, soft, tissue, article, advanced, sarcoma, study, toxicity, rep, trial, treat, thomas, don, clin, oncol, diazooxolnorleucine, clinical, treatment, access, chemotherapy, softtissue, usa, privacy, cookies, content, mesothelioma, acma, toxicities, randomized, publish, research, search, drugs, aclacinomycina, robert, earhart, amato, chang, davis, arm, severe, included, moderate, magill, azotomycin,

Topics {✒️}

6-diazo-5-oxo-l-norleucine versus aclacinomycin alex yuang-chi chang 6-diazo-5-oxo-l-norleucine high-grade soft-tissue sarcomas month download article/chapter high-dose alkylation therapy high-grade softtissue sarcomas advanced soft-tissue sarcomas yuang-chi chang related subjects human neoplastic disease soft tissue sarcoma privacy choices/manage cookies soft-tissue sarcomas soft tissue sarcomas full article pdf high-dose ranimustine cyclophosphamide versus ifosfamide advanced softtissue sarcomas phase ii trial phase ii study randomized prospective trial life-threatening toxicities life-threatening myelosuppression treatment included nausea phase ii trials rochester cancer center severe toxicities resulting european economic area malignant fibrous histiocytoma von hoff dd structure-activity relationship phase ii evaluation previously untreated patients prospective randomized evaluation clinical drug development conditions privacy policy initial therapeutic observations preliminary clinical study clinical antitumor activity accepting optional cookies objective tumor response cancer research article investigational fifteen percent experienced journal finder publish 50 mg/m2/day don treatment arm harvard school advanced sarcomas

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas
         description:Ninety-eight patients with previously-treated advanced soft tissue sarcoma, bone sarcoma, or mesothelioma were randomly assigned to one of two intravenous single-agent treatment regimens, either 6-diazo-5-oxo-l-norleucine (DON; brief infusions of 50 mg/m2/day for 5 consecutive days every 4 weeks) or aclacinomycinA (ACM-A, as 30-min infusions of 100 mg/m2 or 85 mg/m2, administered every 3 weeks). Of 43 patients who were evaluable for response, survival and toxicity, there were two responses (5%) produced by ACM-A; one in a male with mesothelioma, and one in a female with malignant fibrous histiocytoma. None of the 36 evaluable patients treated with DON developed an objective tumor response. Median survival was 4.8 months in the DON treatment arm, and 6.8 months in the ACM-A treatment arm. No patients on the DON arm experienced lethal or life-threatening toxicities, and severe toxicities resulting from this treatment included nausea and emesis (10%), stomatitis (2%), gastrointestinal toxicity (2%), and anemia (2%). Moderate toxicities included vomiting (24%), hematologic toxicity (24%), neurologic toxicity (7%), diarrhea (7%), mucositis (5%), fever (5%), palpitations (2%), hepatotoxicity (2%), bleeding (2%) and edema (2%). Fifteen percent experienced at least one severe reaction, and 63% experienced at least one moderate or greater toxicity. ACM-A was associated with four cases of life-threatening myelosuppression (7%); severe toxicities included myelosuppression (11%), neurologic toxicity (4%), diarrhea (2%), respiratory toxicity (2%), pain and muscle spasms (2%), edema (2%), and ulceration following extravasation (2%). Moderate toxicities included diarrhea (9%), mucositis (7%), hepatotoxicity (7%), infection (5%), fever (7%), gastrointestinal toxicity (4%), respiratory (2%), dehydration (2%), cardiac (2%), alopecia (2%), ulceration following extravasation (7%), and edema (2%). Thirty-eight percent of patients on the ACM-A arm developed one or more severe or worse toxicity, and 76% had at least one moderate or worse toxicity. Neither regimen produces useful clinical results in patients with advanced sarcomas or mesotheliomas.
         datePublished:
         dateModified:
         pageStart:113
         pageEnd:119
         sameAs:https://doi.org/10.1007/BF00216936
         keywords:
            6-diazo-5-oxo-L-norleucine
            aclacinomycin-A
            phase II
            sarcoma
            mesothelioma
            Oncology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Robert H. Earhart
               affiliation:
                     name:University of Wisconsin Clinical Cancer Center
                     address:
                        name:University of Wisconsin Clinical Cancer Center, Madison, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David J. Amato
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard School of Public Health
                     address:
                        name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alex Yuang-Chi Chang
               affiliation:
                     name:University of Rochester Cancer Center
                     address:
                        name:University of Rochester Cancer Center, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ernest C. Borden
               affiliation:
                     name:University of Wisconsin Clinical Cancer Center
                     address:
                        name:University of Wisconsin Clinical Cancer Center, Madison, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masanori Shiraki
               affiliation:
                     name:Tufts University School of Medicine
                     address:
                        name:Tufts University School of Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Melissa E. Dowd
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard School of Public Health
                     address:
                        name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert L. Comis
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas E. Davis
               affiliation:
                     name:University of Wisconsin Clinical Cancer Center
                     address:
                        name:University of Wisconsin Clinical Cancer Center, Madison, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas J. Smith
               affiliation:
                     name:Tufts University School of Medicine
                     address:
                        name:Tufts University School of Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas
      description:Ninety-eight patients with previously-treated advanced soft tissue sarcoma, bone sarcoma, or mesothelioma were randomly assigned to one of two intravenous single-agent treatment regimens, either 6-diazo-5-oxo-l-norleucine (DON; brief infusions of 50 mg/m2/day for 5 consecutive days every 4 weeks) or aclacinomycinA (ACM-A, as 30-min infusions of 100 mg/m2 or 85 mg/m2, administered every 3 weeks). Of 43 patients who were evaluable for response, survival and toxicity, there were two responses (5%) produced by ACM-A; one in a male with mesothelioma, and one in a female with malignant fibrous histiocytoma. None of the 36 evaluable patients treated with DON developed an objective tumor response. Median survival was 4.8 months in the DON treatment arm, and 6.8 months in the ACM-A treatment arm. No patients on the DON arm experienced lethal or life-threatening toxicities, and severe toxicities resulting from this treatment included nausea and emesis (10%), stomatitis (2%), gastrointestinal toxicity (2%), and anemia (2%). Moderate toxicities included vomiting (24%), hematologic toxicity (24%), neurologic toxicity (7%), diarrhea (7%), mucositis (5%), fever (5%), palpitations (2%), hepatotoxicity (2%), bleeding (2%) and edema (2%). Fifteen percent experienced at least one severe reaction, and 63% experienced at least one moderate or greater toxicity. ACM-A was associated with four cases of life-threatening myelosuppression (7%); severe toxicities included myelosuppression (11%), neurologic toxicity (4%), diarrhea (2%), respiratory toxicity (2%), pain and muscle spasms (2%), edema (2%), and ulceration following extravasation (2%). Moderate toxicities included diarrhea (9%), mucositis (7%), hepatotoxicity (7%), infection (5%), fever (7%), gastrointestinal toxicity (4%), respiratory (2%), dehydration (2%), cardiac (2%), alopecia (2%), ulceration following extravasation (7%), and edema (2%). Thirty-eight percent of patients on the ACM-A arm developed one or more severe or worse toxicity, and 76% had at least one moderate or worse toxicity. Neither regimen produces useful clinical results in patients with advanced sarcomas or mesotheliomas.
      datePublished:
      dateModified:
      pageStart:113
      pageEnd:119
      sameAs:https://doi.org/10.1007/BF00216936
      keywords:
         6-diazo-5-oxo-L-norleucine
         aclacinomycin-A
         phase II
         sarcoma
         mesothelioma
         Oncology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Robert H. Earhart
            affiliation:
                  name:University of Wisconsin Clinical Cancer Center
                  address:
                     name:University of Wisconsin Clinical Cancer Center, Madison, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Amato
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard School of Public Health
                  address:
                     name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alex Yuang-Chi Chang
            affiliation:
                  name:University of Rochester Cancer Center
                  address:
                     name:University of Rochester Cancer Center, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ernest C. Borden
            affiliation:
                  name:University of Wisconsin Clinical Cancer Center
                  address:
                     name:University of Wisconsin Clinical Cancer Center, Madison, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masanori Shiraki
            affiliation:
                  name:Tufts University School of Medicine
                  address:
                     name:Tufts University School of Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Melissa E. Dowd
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard School of Public Health
                  address:
                     name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert L. Comis
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas E. Davis
            affiliation:
                  name:University of Wisconsin Clinical Cancer Center
                  address:
                     name:University of Wisconsin Clinical Cancer Center, Madison, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas J. Smith
            affiliation:
                  name:Tufts University School of Medicine
                  address:
                     name:Tufts University School of Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:8
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Wisconsin Clinical Cancer Center
      address:
         name:University of Wisconsin Clinical Cancer Center, Madison, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard School of Public Health
      address:
         name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
         type:PostalAddress
      name:University of Rochester Cancer Center
      address:
         name:University of Rochester Cancer Center, Rochester, USA
         type:PostalAddress
      name:University of Wisconsin Clinical Cancer Center
      address:
         name:University of Wisconsin Clinical Cancer Center, Madison, USA
         type:PostalAddress
      name:Tufts University School of Medicine
      address:
         name:Tufts University School of Medicine, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard School of Public Health
      address:
         name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:University of Wisconsin Clinical Cancer Center
      address:
         name:University of Wisconsin Clinical Cancer Center, Madison, USA
         type:PostalAddress
      name:Tufts University School of Medicine
      address:
         name:Tufts University School of Medicine, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Robert H. Earhart
      affiliation:
            name:University of Wisconsin Clinical Cancer Center
            address:
               name:University of Wisconsin Clinical Cancer Center, Madison, USA
               type:PostalAddress
            type:Organization
      name:David J. Amato
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard School of Public Health
            address:
               name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
               type:PostalAddress
            type:Organization
      name:Alex Yuang-Chi Chang
      affiliation:
            name:University of Rochester Cancer Center
            address:
               name:University of Rochester Cancer Center, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Ernest C. Borden
      affiliation:
            name:University of Wisconsin Clinical Cancer Center
            address:
               name:University of Wisconsin Clinical Cancer Center, Madison, USA
               type:PostalAddress
            type:Organization
      name:Masanori Shiraki
      affiliation:
            name:Tufts University School of Medicine
            address:
               name:Tufts University School of Medicine, Boston, USA
               type:PostalAddress
            type:Organization
      name:Melissa E. Dowd
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard School of Public Health
            address:
               name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
               type:PostalAddress
            type:Organization
      name:Robert L. Comis
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Thomas E. Davis
      affiliation:
            name:University of Wisconsin Clinical Cancer Center
            address:
               name:University of Wisconsin Clinical Cancer Center, Madison, USA
               type:PostalAddress
            type:Organization
      name:Thomas J. Smith
      affiliation:
            name:Tufts University School of Medicine
            address:
               name:Tufts University School of Medicine, Boston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:University of Wisconsin Clinical Cancer Center, Madison, USA
      name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
      name:University of Rochester Cancer Center, Rochester, USA
      name:University of Wisconsin Clinical Cancer Center, Madison, USA
      name:Tufts University School of Medicine, Boston, USA
      name:Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, USA
      name:Fox Chase Cancer Center, Philadelphia, USA
      name:University of Wisconsin Clinical Cancer Center, Madison, USA
      name:Tufts University School of Medicine, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(72)

• Monthly income for https://www.springernature.com/gp/authors
• What's the profit of https://link.springernature.com/home/?
• How much does https://order.springer.com/public/cart make?
• Financial intake of https://submission.nature.com/new-submission/10637/3
• What's the income of https://www.springernature.com/gp/librarians/licensing/agc/journals?
• How much profit is http://scholar.google.com/scholar_lookup?&title=Adult%20Soft%20Tissue%20Sarcomas&journal=Ann%20Surg&volume=205&pages=349-359&publication_year=1987&author=Lawrence%2CW&author=Donegan%2CWL&author=Natarajan%2CN&author=Mettlin%2CC&author=Beart%2CR&author=Winchester%2CD making per month?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Metastatic%20Patterns%20in%20Soft-Tissue%20Sarcomas&journal=Arch%20Surg&volume=118&pages=915-918&publication_year=1983&author=Vezeridis%2CMP&author=Moore%2CR&author=Karakousis%2CCP
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Patterns%20of%20Recurrence%20in%20Patients%20With%20High-Grade%20SoftTissue%20Sarcomas&journal=J%20Clin%20Oncol&volume=3&pages=353-366&publication_year=1985&author=Potter%2CDA&author=Glenn%2CJ&author=Kinsella%2CT&author=Glatstein%2CE&author=Lack%2CEE&author=Restrepo%2CC&author=White%2CDE&author=Seipp%2CCA&author=Wesley%2CR&author=Rosenberg%2CSA
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Adjuvant%20Chemotherapy%20for%20Osteosarcoma%3A%20A%20Randomized%20Prospective%20Trial&journal=J%20Clin%20Oncol&volume=5&pages=21-26&publication_year=1987&author=Eilber%2CF&author=Giuliano%2CA&author=Eckardt%2CJ&author=Patterson%2CK&author=Moseley%2CS&author=Goodnight%2CJ?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Prospective%20Randomized%20Evaluation%20of%20Adjuvant%20Chemotherapy%20in%20Adults%20with%20Soft%20Tissue%20Sarcomas%20of%20the%20Extremities&journal=Cancer&volume=52&pages=424-434&publication_year=1983&author=Rosenberg%2CSA&author=Tepper%2CJ&author=Glatstein%2CE&author=Costa%2CJ&author=Young%2CR&author=Baker%2CA&author=Brennan%2CMF&author=Demoss%2CEV&author=Seipp%2CC&author=Sindelar%2CWF&author=Sugarbaker%2CP&author=Wesley%2CR?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=A%20Randomized%20Trial%20for%20the%20Treatment%20of%20High-Grade%20Soft-Tissue%20Sarcomas%20of%20the%20Extremities%3A%20Preliminary%20Observations&journal=J%20Clin%20Oncol&volume=4&pages=552-558&publication_year=1986&author=Gherlinzoni%2CF&author=Bacci%2CG&author=Picci%2CP&author=Capanna%2CR&author=Calderoni%2CR&author=Lorenzi%2CEG&author=Bernini%2CM&author=Emiliani%2CE&author=Barbieri%2CE&author=Normand%2CA&author=Campanacci%2CM?
• How much profit is http://scholar.google.com/scholar_lookup?&title=Chemotherapy%20of%20advanced%20softtissue%20sarcomas%20in%20adults&journal=Cancer%20Treat%20Rev&volume=4&pages=67-86&publication_year=1977&author=Pinedo%2CHM&author=Kenis%2CY making per month?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Chemotherapy%20for%20Soft%20Tissue%20Sarcoma&journal=Surg%20Gyn%20Obstet&volume=162&pages=193-198&publication_year=1986&author=Greenall%2CMJ&author=Magill%2CGB&author=DeCosse%2CJJ&author=Brennan%2CMF?
• How much does http://scholar.google.com/scholar_lookup?&title=Azaserine%2C%20DON%2C%20and%20Azotomycin%3A%20Three%20Diazo%20Analogs%20of%201-Glutamine%20with%20Clinical%20Antitumor%20Activity&journal=Cancer%20Treat%20Rep&volume=63&pages=1033-1038&publication_year=1979&author=Catane%2CR&author=Hoff%2CDD&author=Glaubiger%2CDL&author=Muggia%2CFM generate monthly?
• How much income is http://scholar.google.com/scholar_lookup?&title=Azotomycin%20%28NSC-56654%29%3A%20biologic%20fate%20in%20mice%20and%20man&journal=Cancer%20Chemother%20Rep&volume=55&pages=47-52&publication_year=1971&author=Pittillo%2CRF&author=Woolley%2CC&author=Brockman%2CRW&author=Ho%2CDH earning monthly?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Phase%20II%20Study%20of%20Azotomycin%20%28NSC%2056654%29&journal=Cancer%20Chemother%20Rep&volume=52&pages=611-614&publication_year=1968&author=Weiss%2CAJ&author=Ramirez%2CG&author=Grage%2CT&author=Strawitz%2CJ&author=Goldman%2CL&author=Downing%2CV
• http://scholar.google.com/scholar_lookup?&title=Phase%20II%20Study%20of%20Azotomycin%20in%20Sarcomas&journal=Cancer%20Treat%20Rep&volume=61&pages=1719-1720&publication_year=1977&author=Chang%2CP&author=Wiernik%2CPH's revenue stream
• See how much http://scholar.google.com/scholar_lookup?&title=Pharmacological%20and%20Initial%20Therapeutic%20Observations%20on%206-diazo-5-oxo-l-norleucine%20%28DON%29%20in%20Human%20Neoplastic%20Disease&journal=Cancer&volume=10&pages=1138-1150&publication_year=1957&author=Magill%2CGB&author=Myers%2CWPL&author=Reilly%2CHC&author=Putnam%2CRC&author=Magill%2CJW&author=Sykes%2CMP&author=Escher%2CGC&author=Karnofsky%2CDA&author=Burchenal%2CJH makes per month
• How profitable is http://scholar.google.com/scholar_lookup?&title=Phase%20I%20Study%20of%206-diazo-5-oxo-l-norleucine%20%28DON%29&journal=Cancer%20Treat%20Rep&volume=64&pages=1247-1251&publication_year=1980&author=Sklaroff%2CRB&author=Casper%2CES&author=Magill%2CGB&author=Young%2CCW?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Phase%20I%20Trial%20of%206-Diazo-5-oxo-l-norleucine%20%28DON%29%20Administered%20by%205-Day%20Courses&journal=Cancer%20Treat%20Rep&volume=66&pages=1215-1217&publication_year=1982&author=Earhart%2CRH&author=Koeller%2CJM&author=Davis%2CHL
• How much profit does http://scholar.google.com/scholar_lookup?&title=Structure-Activity%20Relationship%20of%20Anthracycline%20Relative%20to%20Effects%20on%20Macromolecular%20Synthesis&journal=Mol%20Pharmacol&volume=14&pages=290-298&publication_year=1978&author=Crooke%2CST&author=Duvernay%2CVH&author=Galvan%2CL&author=Prestayko%2CAW generate?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=New%20Antitumor%20Antibiotics%2C%20Aclacinomycin%20A%20and%20B&journal=J%20Antibiot&volume=28&pages=830-834&publication_year=1975&author=Oki%2CT&author=Matsuzawa%2CY&author=Yoshimoto%2CA&author=Numata%2CK&author=Kitamura%2CI&author=Hori%2CS&author=Takamatsu%2CA&author=Umezawa%2CH&author=Ishizuka%2CM&author=Naganawa%2CH&author=Suda%2CH&author=Hamada%2CM&author=Takeuchi%2CT?
• http://scholar.google.com/scholar_lookup?&title=Preliminary%20Clinical%20Study%20of%20Aclacinomycin%20A&pages=75-81&publication_year=1980&author=Majima%2CH's total income per month
• Earnings of http://scholar.google.com/scholar_lookup?&title=Clinical%20Study%20of%20Aclacinomycin%20A&journal=Cancer%20Treat%20Rep&volume=63&pages=931-934&publication_year=1979&author=Ogawa%2CJ&author=Inagaki%2CJ&author=Horikoshi%2CN&author=Inoue%2CK&author=Chinen%2CT&author=Ueoka%2CH&author=Nagura%2CE
• Financial intake of http://scholar.google.com/scholar_lookup?&title=The%20randomization%20and%20stratification%20of%20patients%20to%20clinical%20trials&journal=J%20Chronic%20Dis&volume=27&pages=365-375&publication_year=1974&author=Zelen%2CM
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20bleomycin%2C%20chlorozotocin%2C%20MGBG%2C%20and%20bruceantin%20in%20patients%20with%20advanced%20soft%20tissue%20sarcoma%2C%20bone%20sarcoma%2C%20or%20mesothelioma&journal=Invest%20New%20Drugs&volume=3&pages=397-401&publication_year=1985&author=Amato%2CDA&author=Borden%2CEC&author=Shiraki%2CM&author=Enterline%2CHT&author=Rosenbaum%2CC&author=Davis%2CHL&author=Paul%2CAR&author=Stevens%2CCM&author=Lerner%2CHJ is on a monthly basis
• See how much http://scholar.google.com/scholar_lookup?&title=Phase%20II%20Study%20of%20Aclarubicin%20in%20Previously%20Untreated%20Patients%20with%20Advanced%20Soft%20Tissue%20Sarcomas%3A%20A%20South-western%20Cancer%20Study%20Group%20Trial&journal=Cancer%20Treat%20Rep&volume=69&pages=725-726&publication_year=1985&author=Bertrand%2CM&author=Multhauf%2CP&author=Bartolucci%2CA&author=Ellison%2CD&author=Gockerman%2CJ makes per month
• See how much http://scholar.google.com/scholar_lookup?&title=Clinical%20drug%20development%3A%20An%20analysis%20of%20phase%20II%20trials%2C%201970%E2%80%931985&journal=Cancer%20Treat%20Rep&volume=71&pages=71-80&publication_year=1987&author=Marsoni%2CS&author=Hoth%2CD&author=Simon%2CR&author=Leyland-Jones%2CB&author=Rosa%2CM&author=Wittes%2CRE makes per month
• http://scholar.google.com/scholar_lookup?&title=Phase%20II%20Trial%20of%20Anguidine%20in%20Patients%20With%20Sarcomas%20Unresponsive%20to%20Prior%20Chemotherapy%3A%20A%20Southwest%20Oncology%20Group%20Study&journal=Cancer%20Treat%20Rep&volume=65&pages=881-882&publication_year=1981&author=Thigpen%2CJT&author=Vaughn%2CC&author=Stuckey%2CWJ's financial summary
• Monthly income for http://scholar.google.com/scholar_lookup?&title=N-%28Phosphonacetyl%29-1-aspartate%20%28PALA%29%20in%20Advanced%20Soft%20Tissue%20Sarcoma%3A%20a%20Phase%20II%20Trial%20of%20the%20EORTC%20Soft%20Tissue%20Sarcoma%20Group&journal=Eur%20J%20Clin%20Oncol&volume=18&pages=81-84&publication_year=1982&author=Bramwell%2CV&author=Oosterom%2CA&author=Mouridsen%2CHT&author=Cheix%2CF&author=Somers%2CR&author=Thomas%2CD&author=Rozencweig%2CM
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Carminomycin%20vs%20Adriamycin%20in%20Advanced%20Soft%20Tissue%20Sarcomas%3A%20an%20EORTC%20Randomized%20Phase%20II%20Study&journal=Eur%20J%20Cancer%20Clin%20Oncol&volume=19&pages=1097-1104&publication_year=1983&author=Bramwell%2CVHC&author=Mouridsen%2CHT&author=Mulder%2CJH&author=Somers%2CR&author=Oosterom%2CAT&author=Santoro%2CA&author=Thomas%2CD&author=Sylvester%2CR&author=Markham%2CD?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Phase%20II%20Study%20of%20Elliptinium%20in%20Metastatic%20Soft%20Tissue%20Sarcoma&journal=Eur%20J%20Cancer%20Clin%20Oncol&volume=21&pages=591-593&publication_year=1985&author=Somers%2CR&author=Rouesse%2CJ&author=Oosterom%2CA&author=Thomas%2CD?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Fludarabine%20Phosphate%3A%20Phase%20II%20Evaluation%20in%20Advanced%20Soft-Tissue%20Sarcomas&journal=Am%20J%20Clin%20Oncol&volume=10&pages=341-343&publication_year=1987&author=Pazdur%2CR&author=Samson%2CMK&author=Baker%2CLH bring in?
• How much does http://scholar.google.com/scholar_lookup?&title=High-dose%20alkylation%20therapy%20using%20ifosfamide%20infusion%20with%20mesna%20in%20the%20treatment%20of%20adult%20advanced%20soft-tissue%20sarcoma&journal=Cancer%20Chemother%20Pharmacol&volume=11&pages=69-72&publication_year=1983&author=Stuart-Harris%2CRC&author=Harper%2CPG&author=Parsons%2CCA&author=Kaye%2CSB&author=Mooney%2CCA&author=Gowing%2CNF&author=Wiltshaw%2CE generate monthly?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Cyclophosphamide%20versus%20Ifosfamide%3A%20Final%20Report%20of%20a%20Randomized%20Phase%20II%20Trial%20in%20Adult%20Soft%20Tissue%20Sarcomas&journal=Eur%20J%20Cancer%20Clin%20Oncol&volume=23&pages=311-321&publication_year=1987&author=Bramwell%2CVHC&author=Mouridsen%2CHT&author=Santoro%2CA&author=Blackledge%2CG&author=Somers%2CR&author=Verwey%2CJ&author=Dombernowsky%2CP&author=Onsrud%2CM&author=Thomas%2CD&author=Sylverter%2CR&author=Oosterom%2CA
• What's the total monthly financial gain of https://citation-needed.springer.com/v2/references/10.1007/BF00216936?format=refman&flavour=references?
• What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20H.%20Earhart?
• Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20H.%20Earhart%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20J.%20Amato?
• What is the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20J.%20Amato%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alex%20Yuang-Chi%20Chang?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alex%20Yuang-Chi%20Chang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ernest%20C.%20Borden?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ernest%20C.%20Borden%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• Learn how profitable https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masanori%20Shiraki is on a monthly basis
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masanori%20Shiraki%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Melissa%20E.%20Dowd's financial summary
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Melissa%20E.%20Dowd%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earn?
• What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20L.%20Comis?
• Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20L.%20Comis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20E.%20Davis rake in every month?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20E.%20Davis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20J.%20Smith generate?
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20J.%20Smith%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much money does https://s100.copyright.com/AppDispatchServlet?title=Phase%20II%20trial%20of%206-diazo-5-oxo-L-norleucine%20versus%20aclacinomycin-A%20in%20advanced%20sarcomas%20and%20mesotheliomas&author=Robert%20H.%20Earhart%20et%20al&contentID=10.1007%2FBF00216936©right=Kluwer%20Academic%20Publishers&publication=0167-6997&publicationDate=1990-02&publisherName=SpringerNature&orderBeanReset=true generate?
• How much does https://citation-needed.springer.com/v2/references/10.1007/BF00216936?format=refman&flavour=citation make?
• What's the financial gain of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
• Income figures for https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• Earnings of https://www.springernature.com/gp/products
• What's the financial outcome of https://www.springernature.com/gp/librarians?
• Check the income stats for https://www.springernature.com/gp/societies
• Learn how profitable https://www.springernature.com/gp/partners is on a monthly basis
• What are the total earnings of https://www.springer.com/?
• What's the total monthly financial gain of https://www.nature.com/?
• What are the total earnings of https://www.biomedcentral.com/?
• How much profit is https://www.palgrave.com/ making per month?
• What's the monthly money flow for https://www.apress.com/?
• How much income does https://www.springernature.com/gp/legal/ccpa have?
• What are the earnings of https://www.springernature.com/gp/info/accessibility?
• What's the revenue for https://support.springernature.com/en/support/home?
• How much income is https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations earning monthly?
• What's the monthly income of https://www.springernature.com/?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref